Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). In a filing disclosed on April 07th, the Representative disclosed that they had bought between $1,001 and $15,000 in Supernus Pharmaceuticals stock on March 24th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 - $50,000 in shares of PTC NASDAQ: PTC on 4/1/2025.
• Sold $1,001 - $15,000 in shares of W. R. Berkley NYSE: WRB on 4/1/2025.
• Sold $15,001 - $50,000 in shares of GoDaddy NYSE: GDDY on 4/1/2025.
• Purchased $1,001 - $15,000 in shares of Ford Motor NYSE: F on 3/31/2025.
• Sold $15,001 - $50,000 in shares of Microsoft NASDAQ: MSFT on 3/31/2025.
• Sold $15,001 - $50,000 in shares of Pfizer NYSE: PFE on 3/31/2025.
• Purchased $1,001 - $15,000 in shares of Boeing NYSE: BA on 3/31/2025.
• Sold $1,001 - $15,000 in shares of Hologic NASDAQ: HOLX on 3/31/2025.
• Sold $15,001 - $50,000 in shares of Merck & Co., Inc. NYSE: MRK on 3/31/2025.
• Sold $1,001 - $15,000 in shares of Tesla NASDAQ: TSLA on 3/31/2025.

Supernus Pharmaceuticals Price Performance

SUPN traded up $0.60 during trading on Friday, hitting $31.67. 407,129 shares of the stock traded hands, compared to its average volume of 492,505. The business has a 50 day moving average price of $33.52 and a 200 day moving average price of $35.07. The company has a market cap of $1.77 billion, a price-to-earnings ratio of 29.60 and a beta of 0.90. Supernus Pharmaceuticals, Inc. has a twelve month low of $25.53 and a twelve month high of $40.28.

Remove Ads

Analysts Set New Price Targets

Several brokerages recently weighed in on SUPN. Cantor Fitzgerald restated a "neutral" rating and set a $36.00 price objective on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th. StockNews.com downgraded shares of Supernus Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Wednesday.

Insiders Place Their Bets

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 700 shares of the company's stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $39.62, for a total transaction of $27,734.00. Following the sale, the vice president now owns 10,149 shares of the company's stock, valued at approximately $402,103.38. This represents a 6.45 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Jonathan Rubin sold 927 shares of Supernus Pharmaceuticals stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the transaction, the senior vice president now directly owns 7,853 shares of the company's stock, valued at approximately $307,444.95. This trade represents a 10.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 11,104 shares of company stock worth $440,263. 9.30% of the stock is currently owned by insiders.

Institutional Trading of Supernus Pharmaceuticals

Several institutional investors have recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in Supernus Pharmaceuticals by 0.4% during the 4th quarter. Vanguard Group Inc. now owns 6,150,759 shares of the specialty pharmaceutical company's stock worth $222,411,000 after buying an additional 22,852 shares during the period. Geode Capital Management LLC raised its position in shares of Supernus Pharmaceuticals by 1.9% during the fourth quarter. Geode Capital Management LLC now owns 1,510,568 shares of the specialty pharmaceutical company's stock worth $54,633,000 after acquiring an additional 28,517 shares during the last quarter. American Century Companies Inc. lifted its stake in shares of Supernus Pharmaceuticals by 9.2% in the fourth quarter. American Century Companies Inc. now owns 1,140,705 shares of the specialty pharmaceutical company's stock worth $41,248,000 after acquiring an additional 95,777 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in Supernus Pharmaceuticals by 5.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 753,363 shares of the specialty pharmaceutical company's stock valued at $27,242,000 after acquiring an additional 40,968 shares during the last quarter. Finally, Northern Trust Corp increased its position in Supernus Pharmaceuticals by 18.3% during the 4th quarter. Northern Trust Corp now owns 717,161 shares of the specialty pharmaceutical company's stock valued at $25,933,000 after purchasing an additional 110,867 shares during the period.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.